| 摘要 |
Disclosed is a use of DPP-4 inhibitor having a structural formula depicted herein and its pharmaceutically acceptable salt for the manufacture of a medicament for use in a method of treating and/or preventing metabolic diseases in patients with insufficient glycemic control despite therapy with one or more conventional oral or non-oral antidiabetic drugs selected from metformin, sulphonylureas, thiazolidinediones, glinides, alpha-glucosidase blockers, GLP-1 or GLP-1 analogues, and insulin or insulin analogues, wherein the medicament is formulated for administration in a daily oral amount of 5 mg., The disclosure also relates to the use of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methly-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine which is a DPP-4 inhibitor for the manufacture of a medicament for use in a method of treating type 2 diabetes in a patient with insufficient glycemic control despite therapy with one or two antihyperglycemic agents selected from metformin, sulphonylureas, thiazolidinediones, pioglitazone, glinides, a-glucosidase blockers, GLP-1 and GLP-1 analogues, and insulin and insulin analogues, wherein said medicament is characterised in that the medicament comprises a daily oral amount of 5 mg of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methly-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine in combination with said one or two antihyperglycemic agents. |
